Main Article Content
Abstract
Dengue fever is the most prevalent arboviral disease, caused by one of four separate but closely related dengue viruses (DENV), and it has a considerable economic and public health impact in endemic areas. A dengue vaccine will be critical in furthering illness management. However, the work has been hampered by the need to induce good protection against all four DENV serotypes, as well as the possibility of an unfavourable effect due to the phenomena that partial immunity to DENV may aggravate symptoms upon future heterotypic infection. The most modern dengue vaccines available today are all tetravalent and based on recombinant live attenuated viruses. Sanofi Pasteur's CYD-TDV vaccine has been licenced for use in people who have previously been infected with dengue. Two other tetravalent live attenuated vaccine candidates: TAK-003 by Takeda and TV003 by National Institute of Allergy and Infectious Diseases, have completed phase 3 and phase 2 clinical trials, respectively.